Cargando…

Amantadine ER (Gocovri(®)) Significantly Increases ON Time Without Any Dyskinesia: Pooled Analyses From Pivotal Trials in Parkinson's Disease

Background: Clinical trials for antiparkinsonian drugs aimed at managing motor complications typically use patient diaries to divide levodopa-induced dyskinesias (LID) into “troublesome” and “non-troublesome” categories. Yet, given the choice, most patients would prefer to live without experiencing...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hauser, Robert A., Walsh, Ryan R., Pahwa, Rajesh, Chernick, Dustin, Formella, Andrea E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Neurology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8032973/ https://www.ncbi.nlm.nih.gov/pubmed/33841311 http://dx.doi.org/10.3389/fneur.2021.645706

Ejemplares similares

Effects of Gocovri (Amantadine) Extended-Release Capsules on Motor Aspects of Experiences of Daily Living in People with Parkinson’s Disease and Dyskinesia
por: Hauser, Robert A., et al.
Publicado: (2021)

EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson’s Disease
por: Tanner, Caroline M., et al.
Publicado: (2020)

Effects of Gocovri (Amantadine) Extended Release Capsules on Non-Motor Symptoms in Patients with Parkinson’s Disease and Dyskinesia
por: Mehta, Shyamal H., et al.
Publicado: (2021)

Clinically important change on the Unified Dyskinesia Rating Scale among patients with Parkinson's disease experiencing dyskinesia
por: Pahwa, Rajesh, et al.
Publicado: (2022)

Prevalence of Dyskinesia and OFF by 30-Minute Intervals Through the Day and Assessment of Daily Episodes of Dyskinesia and OFF: Novel Analyses of Diary Data from Gocovri Pivotal Trials
por: Hauser, Robert A., et al.
Publicado: (2019)

Amantadine extended-release capsules for levodopa-induced dyskinesia in patients with Parkinson’s disease
por: Sharma, Vibhash D, et al.
Publicado: (2018)

Amantadine extended release for levodopa‐induced dyskinesia in Parkinson's disease (EASED Study)
por: Pahwa, Rajesh, et al.
Publicado: (2015)

Case report: Blepharospasm in peak-dose dyskinesia may benefit from amantadine in Parkinson's disease
por: Fan, Qian-Ya, et al.
Publicado: (2022)

Potential utility of amantadine DR/ER in persons with Parkinson’s disease meeting 5-2-1 criteria for device aided therapy
por: Hauser, Robert A., et al.
Publicado: (2021)

Parkinson's Patients with Dyskinesia Switched from Immediate Release Amantadine to Open‐label ADS‐5102
por: Isaacson, Stuart H., et al.
Publicado: (2018)

Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson’s Disease
por: Elmer, Lawrence W., et al.
Publicado: (2018)

Amantadine for Dyskinesias in Parkinson's Disease: A Randomized Controlled Trial
por: Sawada, Hideyuki, et al.
Publicado: (2010)

An updated meta-analysis of amantadine for treating dyskinesia in Parkinson's disease
por: Kong, Min, et al.
Publicado: (2017)

Pharmacokinetics of ADS-5102 (Amantadine) Extended Release Capsules Administered Once Daily at Bedtime for the Treatment of Dyskinesia
por: Hauser, Robert A., et al.
Publicado: (2018)

Randomized, placebo‐controlled trial of ADS‐5102 (amantadine) extended‐release capsules for levodopa‐induced dyskinesia in Parkinson's disease (EASE LID 3)
por: Oertel, Wolfgang, et al.
Publicado: (2017)

Amantadine delayed release/extended release capsules significantly reduce OFF time in Parkinson’s disease
por: Hauser, Robert A., et al.
Publicado: (2022)

ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson’s Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety Study
por: Hauser, Robert A., et al.
Publicado: (2017)

Amantadine and the Risk of Dyskinesia in Patients with Early Parkinson’s Disease: An Open-Label, Pragmatic Trial
por: Kim, Aryun, et al.
Publicado: (2018)

Factors Associated With Dyskinesia in Parkinson's Disease in Mainland China
por: Zhou, Xun, et al.
Publicado: (2019)

Intestinal Decontamination Therapy for Dyskinesia and Motor Fluctuations in Parkinson's Disease
por: Baizabal-Carvallo, José Fidel, et al.
Publicado: (2021)

Opioidergic Modulation of Striatal Circuits, Implications in Parkinson's Disease and Levodopa Induced Dyskinesia
por: Sgroi, Stefania, et al.
Publicado: (2018)

Improvement of Deep Brain Stimulation in Dyskinesia in Parkinson's Disease: A Meta-Analysis
por: Liu, Yun, et al.
Publicado: (2019)

Amantadine, COVID-19 and Parkinsonism
por: Wiwanitkit, Viroj
Publicado: (2020)

Effect of Pre-exposure Use of Amantadine on COVID-19 Infection: A Hospital-Based Cohort Study in Patients With Parkinson's Disease or Multiple Sclerosis
por: Kamel, Walaa A., et al.
Publicado: (2021)

Response to: Amantadine, COVID-19 and Parkinsonism
por: Aranda-Abreu, Gonzalo Emiliano
Publicado: (2020)

The Effect of Amantadine on Agitation in the Pediatric Traumatic Brain Injury Population: A Case Series
por: Hon, Emily, et al.
Publicado: (2023)

Remnants of Cardinal Symptoms of Parkinson's Disease, Not Dyskinesia, Are Problematic for Dyskinetic Patients Performing Activities of Daily Living
por: Goubault, Etienne, et al.
Publicado: (2019)

Blood Flow and Glucose Metabolism Dissociation in the Putamen Is Predictive of Levodopa Induced Dyskinesia in Parkinson's Disease Patients
por: Aljuaid, Maram, et al.
Publicado: (2019)

Concussion-Induced Oromandibular Dyskinesia
por: Zhang, Brenda, et al.
Publicado: (2023)

Fluvoxamine and Amantadine: Central Nervous System Acting Drugs Repositioned for COVID-19 as Early Intervention
por: Rejdak, Konrad, et al.
Publicado: (2022)

Serial I-123-FP-CIT SPECT Image Findings of Parkinson's Disease Patients With Levodopa-Induced Dyskinesia
por: Jeong, Eun Hye, et al.
Publicado: (2018)

Transcranial Magnetic Stimulation Alleviates Levodopa-Induced Dyskinesia in Parkinson's Disease and the Related Mechanisms: A Mini-Review
por: Wu, Yi, et al.
Publicado: (2021)

Evaluation of the Direct Effect of Bilateral Deep Brain Stimulation of the Subthalamic Nucleus on Levodopa-Induced On-Dyskinesia in Parkinson's Disease
por: Li, Jiping, et al.
Publicado: (2021)

Associations Between Amantadine Usage, Gait, and Cognition in PSP: A post-hoc Analysis of the Davunetide Trial
por: Dale, Marian L., et al.
Publicado: (2020)

The serotonergic system in Parkinson’s patients with dyskinesia: evidence from imaging studies
por: Pagano, Gennaro, et al.
Publicado: (2017)

The Rodent Models of Dyskinesia and Their Behavioral Assessment
por: Peng, Qiwei, et al.
Publicado: (2019)

Tardive Dyskinesia Following Low-Dose Risperidone
por: Rokon, Ahmad E, et al.
Publicado: (2022)

The Relationship Between Electrical Energy Delivered by Deep Brain Stimulation and Levodopa-Induced Dyskinesias in Parkinson's Disease: A Retrospective Preliminary Analysis
por: Prenassi, Marco, et al.
Publicado: (2021)

Amantadine: reappraisal of the timeless diamond—target updates and novel therapeutic potentials
por: Danysz, Wojciech, et al.
Publicado: (2021)

Amantadine-Induced Patulous Eustachian Tubes in Parkinson's Disease
por: Boyd, J. T., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_6m85lmv5grj6g7hpf2n7lks9j7